clinical trial · NCT05494411
Named Patient Program for Mitomycin for Pyelocalyceal Solution
Urothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial CarcinomaUrothelial Carcinoma RecurrentMitomycin for pyelocalyceal solution
brief summary
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
started
—
primary completion
—
completion
—
last updated
Feb 28, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol